LEA GRIPPIN: Open Payments
NPI 1891204475 · NORTHAMPTON, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,380 in 109 payments from 20 companies in 2025. Trend: 2023 $125 · 2024 $1,503 · 2025 $2,380
Food & beverage: $2,280Education: $100
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 20 | $481 |
| Regeneron Healthcare Solutions, Inc. | 16 | $287 |
| CSL Behring | 8 | $228 |
| Amgen Inc. | 12 | $204 |
| Genentech USA, Inc. | 10 | $201 |
| GENZYME CORPORATION | 8 | $159 |
| GlaxoSmithKline, LLC. | 6 | $139 |
| Lilly USA, LLC | 5 | $116 |
| SANOFI-AVENTIS U.S. LLC | 1 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $96 |
Products named: DUPIXENT, TEZSPIRE, Xolair, FASENRA, AIRSUPRA, EBGLYSS, TRELEGY ELLIPTA, TAKHZYRO.
Industry payments across MA — which companies pay providers there.
